MPH Part 5 - Dosage

71% of children with ADHD-HI or ADHD-C (then known as ADD+H) were recommended a moderate-to-high dose (in this case, 10 or 15 mg of MPH twice daily, which by today’s standards would be considered moderate doses). (RCT, crossover, n = 40 children, 3 dose levels, full text not available to us, E 1b.)¹ According to a review, more than two-thirds of children with ADHD respond to moderate to high doses of MPH. (Narrative review, E 4.)²
“The last 10 mg” are particularly important for achieving optimal results. (book chapter, expert opinion, E 4)³
When adjusting the dosage, therefore, one should not stop increasing the dose too soon. Emotional numbness (“zombie”) is a sign of an overdose. (ADxS experience)

Striatal binding to DAT (dopamine transporter) decreased by 51% in healthy individuals aged 18 to 83, at a rate of approximately 8% per decade of life. (Cross-sectional study, SPECT, n = 28, full text not available to us, E 3.)⁴ Among 22- to 80-year-olds, DAT density decreased by 7.6% (caudate nucleus) and 7.7% (putamen), respectively, per decade of life. (Cross-sectional study, PET, n = 36, E 3.)⁵ Children were not included in the study. Whether adults therefore require less MPH has not been established (see below). For adults, a starting dose of no more than 5 mg every 3 hours (immediate release) is recommended. (ADxS assessment)

6. MPH Dosage¶

For detailed information on dosing MPH and stimulants, see Dosage of Medications for ADHD

6.1. MPH should not be calculated based solely on weight or age¶

Methylphenidate is not dosed uniformly “based on body weight.” In children and adolescents, there was no correlation between the dose determined during open-label titration and body weight. (RCT, data from open-label dose-finding phase, n = 230 randomized, n = 221 in open-label phase, 1 week double-blind + 11 weeks open-label, manufacturer-funded, E 2b for these data.)⁷ In contrast, a naturalistic study considered body weight to be a reliable parameter for dose titration. (cross-sectional study, naturalistic, n = 59, E 2b.)⁸ Some people with ADHD are able to manage with very low doses of MPH (3 to 5 mg every 3 hours). (ADxS experience) Others require the maximum recommended dose of 1 mg/kg of body weight per day.
The maximum dose of 1 mg/kg of body weight per day applies primarily to children. In studies of children and adolescents up to 18 years of age, in which the appropriate MPH dose was determined in stages, the established maximum doses ranged from 0.8 mg/kg/day to 1.8 mg/kg/day. No discernible scientific rationale was found for any of these maximum doses. (Meta-analysis, k = 49 (11 RCTs, 38 cohort studies), n = 5,524 in cohort studies, n = 1,304 MPH + 887 controls in RCTs, E 2b.)⁹ For people with ADHD who tolerate MPH well but experience only a moderate effect at lower doses, a dosage of more than 1 mg/kg/day may also be tested. (textbook, full text not accessible to us, E 4)¹⁰

Among adults with ADHD and substance use disorder, the prescribed daily dose of MPH (30 to 600 mg, median 160 mg) did not correlate with body weight (rs = 0.12). The daily dose relative to body weight varied by a factor of 23 among patients. (observational study, n = 28, E 2b.)¹¹ In a meta-analysis of placebo-controlled studies in children and adolescents, studies using weight-based dosing showed greater effects than those using fixed dosing (coefficient 0.24, 95% CI 0.06 to 0.41). (Meta-analysis, k = 48 RCTs, N = 4,964, E 1a.)¹²

Significant Individual Variations in Dosage Requirements¶

The most recent daily dose of flexibly dosed OROS-MPH varied widely among adults: (Open-label study (extension of an RCT), n = 370, 7 weeks, authors employed by the manufacturer, E 2b.)¹³

• 7.9% with 18 mg
• 29.3% with 36 mg
• 34.4% with 54 mg
• 19.8% with 72 mg
• 8.7% with 90 mg

In children and adolescents (ages 6 to 18), the final dose of sustained-release MPH (Aptensio XR) was distributed as follows after an 11-week open-label dose-finding phase: (RCT, data from the open-label dose-finding phase, n = 230 randomized, n = 221 in the open-label phase, 1 week double-blind + 11 weeks open-label, manufacturer-funded, Phase 2b for these data.)⁷

• 1.5% with 10 mg
• 2.0% with 15 mg
• 16.8% with 20 mg
• 27.7% with 30 mg
• 25.2% with 40 mg
• 17.8% with 50 mg
• 8.9% with 60 mg

In an RCT involving adults, the consequences of a fixed-dose phase (40, 60, or 80 mg MPH-LA/day) were individualized dose titration. Afterward, a similar number of patients were optimally controlled on 40, 60, and 80 mg/day, respectively (152, 177, and 160). (RCT, n = 725, 40 weeks, manufacturer-funded, E 1b.)¹⁴ Two-thirds of the patients required a different dose than the one initially assigned following individual titration. (Post-hoc analysis of an open-label phase of an RCT, n = 584, 5 weeks, manufacturer-funded, E 2b.)¹⁵

The optimal daily dose of MPH ranged from 18 to 180 mg. In contrast, weight- and dose-adjusted blood levels of MPH did not differ among the age groups studied when using OROS-MPH. (Cross-sectional study, naturalistic, n = 59, E 2b.)⁸ Response, required dose, and side effects vary considerably from person to person. (Systematic review and meta-analysis, E 3.)¹⁶ Factors influencing these include, among others, genetic variability, body weight, age, sex, development of tolerance, interactions with other medications, and comorbidities. (Narrative review with unpublished study data; authors employed by the manufacturer, E 4.)¹⁷ Individuals carrying the CES1-143E gene variant (CES1: carboxylesterase 1, the primary metabolizing enzyme for MPH) had more than twice the d-MPH exposure after 10 mg of MPH (median AUC 53.3 vs. 21.4 ng·h/mL, half-life 4.0 vs. 2.6 hours). The variant was found in 6 out of 200 healthy Danes (allele frequency 1.6%). (Pharmacokinetic study, n = 44 healthy subjects, single dose, Phase 2b.)¹⁸ However, due to their rarity, CES1 variants are considered an unlikely explanation for dose variability. (cross-sectional study, naturalistic, n = 59, E 2b.)⁸

Adults required a higher absolute daily dose than children (median 72 vs. 36 mg) at the same weight-based dose (1.0 mg/kg). (Cross-sectional study, naturalistic, n = 59, E 2b.)⁸ Nevertheless, some adults manage with very low daily doses. (ADxS experience)

Dose-response curve¶

(E 1b): The dose-response curve for immediate release MPH on academic performance and classroom behavior was as follows:

• Children: linear doses (0.15, 0.3, and 0.6 mg/kg) for reading comprehension, math performance (quantity and accuracy), spelling, disruptive behavior, and task-related behavior (RCT, double-blind, crossover, n = 29, 5 weeks, E 1b.)¹⁹
• For adolescents, the response was predominantly flat. The greatest improvement was usually observed between the placebo and the 10 mg dose (in the morning and at noon, plus 5 mg in the afternoon, averaging 0.18 mg/kg per dose). Many adolescents did not benefit from higher doses; some experienced a worsening of symptoms. An increase from 20 to 30 mg tended to lead to a worsening rather than a significant improvement (RCT, double-blind, crossover, n = 45, 6 weeks, E 1b.)²⁰

In children and adolescents, the effect of MPH on ADHD symptoms increased as the daily dose rose to about 45 mg and then leveled off:

• Meta-analysis of fixed doses (Chang 2026): Strongest effect at 45 mg/day (SMD 1.06, 95% CI 0.91 to 1.22); weaker effect at 60 mg/day (SMD 0.70, 0.48 to 0.94). Discontinuations due to side effects increased from 1.4% (10 mg) to 8.2% (60 mg). The best net benefit in terms of efficacy and risk of discontinuation was achieved at doses of 18 to 46 mg/day (optimum 30 to 39 mg/day) when weighted neutrally. (Meta-analysis, k = 48 RCTs, N = 4,964, E 1a.)¹²
• Dose-response network meta-analysis (Nourredine 2026): Peak effect at approximately 45 mg/day (SMD −0.89, 95% CI −1.18 to −0.60); no additional benefit above this dose. No dose-dependent risk of discontinuation was found in children (maximum 2.7% at approximately 50 mg/day compared with 1.3% on placebo). (Meta-analysis, k = 68 RCTs in children and adolescents, N = 14,138, E 1a.)²¹
• Neurocognition (Vertessen 2022): MPH improved all neurocognitive functions examined (d = 0.20 to 0.73). As the dose increased (0.10 to 1.00 mg/kg per single dose), ADHD symptoms improved (SMD 0.95 across all doses), reaction variability, and non-executive memory; however, baseline reaction speed improved more significantly at high doses (0.61 to 1.00 mg/kg) than at low and moderate doses, while executive functions (working memory, inhibition, cognitive flexibility), however, did not. No adverse effects of high doses on cognition were found. (meta-analysis, k = 31, N = 804, E 1a.)²²

At the individual child level, the dose-response curve was inconsistent. When alternating weekly between placebo and 5, 10, 15, and 20 mg of MPH twice daily, 73 to 88% of the children showed dose-dependent improvement in symptoms, while in 12 to 27%, higher doses did not result in further improvement. Side effects increased with dose in 59 to 60% of the children. (RCT, crossover, n = 45, 5 weeks, E 1b.)²³

In adults, the effect of MPH increased with dose, with diminishing additional benefit at higher doses:

• For every additional 10 mg of MPH, the SMD increases by 0.11 to 0.12 (metaregression; at an average dose of 57.4 mg/day, the SMD is 0.57 to 0.58). (Meta-analysis, k = 18 RCTs, N = 2,045, E 1a.)²⁴
• ED50 at 25 mg/day, ED95 at 72.5 mg/day; additional benefit decreases progressively above 35 to 40 mg/day. (meta-analysis, k = 47 RCTs, N = 7,714, E 1a.)²⁵
• Increasing efficacy across the entire dose range studied, with no discernible plateau, though the rate of improvement slowed starting at approximately 50 mg/day. (Meta-analysis, k = 45 RCTs in adults, N = 11,016, E 1a.)²¹
• Fixed doses of 18, 36, and 72 mg of OROS-MPH reduced symptoms (CAARS) by 10.6, 11.5, and 13.7 points, compared with 7.6 points for placebo. The response rates were 50.5%, 48.5%, and 59.6%, compared with 27.4%. Adverse events occurred in 75%, 76%, and 82% of patients, compared with 66% in the placebo group. Discontinuations due to side effects rose from 1.0% (18 mg) to 3.9% (36 mg) to 7.8% (72 mg), compared with 1.0% in the placebo group, Decreased appetite increased from 19.8% to 21.6% to 34.3%, compared with 7.3%. (RCT, n = 401, 5 weeks, manufacturer-funded, author(s) employed by the manufacturer, E 1b.)²⁶

Studies using flexible titration did not show a significantly greater effect in adults than studies using a fixed dose (SMD 0.53, 95% CI 0.31 to 0.75, compared with 0.40, 0.08 to 0.72, p = 0.485). (meta-analysis, k = 18 RCTs, N = 2,045, E 1a.)²⁴

High doses¶

Doses above the recommended limit (FDA: 60 mg/day) provided, on average, only a slight additional benefit in adults, while resulting in more discontinuations due to side effects:

• Compared with approved doses, unapproved doses reduced symptoms slightly more (SMD −0.23, 95% CI −0.44 to −0.02, very low certainty of evidence) and doubled the risk of discontinuation due to side effects (OR 2.02, 95% CI 1.19 to 3.43). For every mg/day, this risk of discontinuation increased by 2.23% (95% CI 1.11 to 3.35%). (Meta-analysis, k = 47 RCTs, N = 7,714, E 1a.)²⁵
• The risk of discontinuation due to side effects was 7.3% (95% CI 4.3 to 12.0) at 60 mg/day and 10.0% (5.0 to 19.8) compared with 2.6% for placebo, while the effect improved only from an SMD of −0.38 to −0.52. (Meta-analysis, k = 45 RCTs in adults, N = 11,016, E 1a.)²¹

In adolescents (ages 11 to 20) taking an average of 169 mg of OROS-MPH daily (126 to 270 mg, 3.0 mg/kg) and an average of 2.2 additional medications, the mean plasma MPH concentration 4 to 5 hours after administration was 28 ng/ml (15.5 to 49.0 ng/ml). No patient reached 50 ng/mL or showed signs of stimulant intoxication. Plasma levels and dose did not correlate. (Cross-sectional study, naturalistic, retrospective, n = 17, E 3.)²⁷ Children who, following gradual dose adjustment, were titrated to high stimulant doses (MPH above 2 mg/kg/day or above 108 mg/day) through gradual dose adjustment showed greater growth retardation than children on a standard dose (change in height z-score −0.41 versus −0.09). This growth delay predominantly occurred before the high dose was reached. No other serious complications were reported. The most common reason for dose reduction was that the higher dose provided no additional benefit. Fifty of the 52 children receiving high doses were treated with MPH (maximum dose 216 mg/day or 3.1 mg/kg/day). Blood pressure showed no consistent correlation with the dose. (Retrospective case-control chart study, n = 52 high dose, n = 118 usual dose, average follow-up of 4 years, E 3.)²⁸

Low Dosage Requirements for ADHD-I and Autism¶

People with the ADHD-I presentation form appear to require lower doses particularly frequently. Among children with ADHD-I (formerly ADD-H), 24% did not respond to MPH, and 35% responded best to the low dose (5 mg twice daily). (RCT, crossover, n = 40 children, 3 dose levels, full text not available to us, E 1b.)¹ Among children (ages 5 to 14) with profound developmental disorders and hyperactivity, 49% responded to MPH (effect size 0.20 to 0.54), and 18% discontinued treatment due to side effects. 16 of 66 children could not tolerate the highest dose (approximately 0.5 mg/kg per single dose). The effect was weaker and side effects were more common than in typically developing children with ADHD. (RCT, crossover, n = 72, 4 weeks, E 1b.)²⁹ People with ASS seem to require lower doses even more frequently. (ADxS experience)
We are aware of several cases of adults with ADHD for whom a single dose of 1.25 mg of immediate-release MPH is the optimal dosage. (ADxS experience)

Dose Adjustment During the Menstrual Cycle¶

For women with premenstrual worsening of ADHD and mood symptoms, the stimulant dose was increased by 30 to 50 percent 3 to 10 days before the onset of menstruation. All 9 women reported better control of ADHD and mood symptoms with minimal side effects and continued with the adjustment. Two received MPH preparations (sustained release MPH from 72 to 108 mg, sustained release dexmethylphenidate from 20 to 30 mg); the others received lisdexamfetamine or dexamfetamine. (case series, n = 9, 6 to 24 months, E 4.)³⁰

6.2. Daily Coverage MPH¶

It is definitely recommended to use MPH in such a way that it covers the entire day, but not the late evening and night. (ADxS assessment)

For information on the varying durations of action of the individual MPH medications, see section 7 below.

6.3. Dose Adjustment for Methylphenidate¶

6.3.1. Gradual introduction in small steps¶

It is important to titrate the dose slowly and persistently. In our opinion, the standard titration practice in Germany is significantly too rapid. (ADxS assessment)
As a general rule, MPH should be started at a low dose and the dosage should be increased only gradually. Even if the optimal dosage were known, an immediate optimal dosage could potentially be too much for the patient to handle (lay/self-help website, E 4)³² and exacerbate side effects. (textbook, full text not accessible to us, E 4)³³

Dosage adjustment should begin with 2.5 mg to a maximum of 5 mg every 3 to 4 hours, which should only be increased to 3 x 5 = 15 mg per day within the first few days. Trials with higher starting doses not only failed to produce better efficacy results but actually yielded worse outcomes and, at the same time, resulted in a significantly higher discontinuation rate due to side effects. (Textbook, full text not accessible to us, E 4)³³ * (E 4): Others recommend 2.5 to 5 mg twice daily, with a weekly increase of 2.5 to 5 mg. (Textbook, full text not accessible to us, E 4)¹⁰ * (A psychotherapist’s practice guide, E 4)³⁴ * (Lay/self-help website, E 4)³² * (Textbook, full text not accessible to us, E 4)³³ * (Practice website, E 4)*³⁵ A case series describes titration with liquid MPH in increments of 2.5 to 5 mg every 3 to 4 days. (Case series, n = 2, author employed by the manufacturer, E 4.)³⁶ Since such fine-grained dosing increments do not harm other people with ADHD (but rather help prevent side effects associated with dosing), dosage adjustments in 2.5-mg increments (based on a single immediate-release dose of MPH) should be the gold standard. (ADxS assessment) Kühle agrees. (Practice website, E 4)³⁵ A large meta-analysis found that in studies with flexible titration, higher doses were associated with greater efficacy and fewer discontinuations. It did not comment on the size of the titration increments. (meta-analysis, k = 65 RCTs, N = 7,877, E 1a.)³⁷ A Swiss dosing table recommends starting with 5 mg once or twice daily for children, with a weekly increase in the daily dose of 5 to 10 mg, and starting with 10 mg once daily for adolescents and adults, with a weekly increase of 10 mg. (Clinical table based on the Compendium of Medicines, E 4.)³⁸ For the reasons stated, we consider these dose increments to be too large. (ADxS assessment)

For people with ADHD for whom even extremely small differences in dosage are critical, a pharmacy in Switzerland offers MPH drops. One drop contains 0.35 mg of MPH. It is manufactured in batches and preserved with E216 and E218.³⁹ One person with ADHD reports that dissolving immediate release MPH in alcohol in such precise amounts that they could be measured drop by drop yielded comparable results. (ADxS experience)

• Inform people with ADHD and (informed) third-party observers about the duration of action of the respective medication and the expected rebound effect.
• We believe that up-dosing by 2.5 mg per single dose every 5 to 7 days is appropriate. Dosage increments of 5 mg per dose, which we previously considered acceptable here, are now deemed too high because there is a significant proportion of people with ADHD for whom 2.5 mg less constitutes an underdose and 2.5 mg more constitutes an overdose. (Website, E 4)³⁵ Even if this represents only a minority of people with ADHD, it would constitute medical malpractice to increase the dose more rapidly, since it is impossible to predict in advance which group a person with ADHD belongs to. See also below: Genetic variants influence MPH dosing.
  The younger the person with ADHD is and the less they notice the MPH dose, the more the dosage increments can be increased.
  During titration, the dose is increased until the signs of an overdose become more pronounced with each subsequent dose increase. After that, the dose that optimally reduces symptoms without causing side effects can be determined.
  Unfortunately, there have been reported cases in which doctors have started treatment with single doses of 15 or 20 mg. We strongly advise against this. (ADxS assessment)
  Even if this were the correct dosage for a few people with ADHD, such a high initial dose would significantly increase their risk of experiencing much more severe side effects in the first few weeks compared to a slower titration.

6.3.2. No Caffeine When Taking MPH¶

Caffeine (theine is also caffeine), theobromine (dark cocoa), and other stimulants should be strictly avoided when adjusting the dosage. Caffeine, which was previously tolerated without any problems, can suddenly trigger internal tremors and other symptoms when taken simultaneously with stimulants—symptoms that may then be mistakenly interpreted as side effects of the medication. When first adjusting the dosage of stimulants, caffeine can trigger sensations similar to an overdose. Once the stimulant dosage has been stabilized, caffeine can be reintroduced. Any adverse sensations can then be correctly attributed to the caffeine. (Experience with ADxS)

6.3.3. No nicotine withdrawal with a single dose of MPH¶

Nicotine withdrawal that begins at the same time as dosing may skew the results. The effect of MPH on smoking behavior is inconsistent. Acute administration of MPH (5 to 40 mg) increased the number of cigarettes smoked in a dose-dependent manner among smokers without ADHD (placebo-controlled crossover study, double-blind, n = 10, single doses, E 2a.)⁴⁰ and also increased it among smokers with ADHD (at doses below 10 and 40 mg, but not below 20 mg). (Placebo-controlled crossover study, double-blind, n = 9, single doses, E 2a.)⁴¹ In 12 adolescent female smokers (ages 14 to 19) with ADHD and borderline disorder, nicotine dependence (FTND) decreased from 4.1 to 2.0 points over 8 weeks of MPH treatment (0.3 to 0.6 mg/kg/day). (Open-label study, n = 12, 8 weeks, E 2b.)⁴²
Similarly, patients should avoid resuming nicotine use while titrating the dose of stimulants.

6.3.4. Age-Related Differences in Dosage¶

Since adults have significantly fewer dopamine transporters than children (50-year-olds have only half as many as 10-year-olds (textbook, E 4)⁴³ ), a much lower dosage is indicated for adults than for children.

Preschoolers (ages 4 to 5) metabolized immediate release MPH more slowly than school-age children (ages 6 to 8). At the same weight-based dose, the dose-normalized peak concentration was higher (p = 0.003) and clearance was slower (p = 0.0002). The mean half-life was 3.82 hours compared to 2.18 hours. Preschoolers were thus exposed to higher MPH levels at the same mg/kg dose. (Comparative pharmacokinetic study, n = 23, single dose after titration, Phase 2b.)⁴⁴

In the Preschool ADHD Treatment Study (PATS) involving 3- to 5-year-olds, the mean daily dose of MPH increased from 14.1 mg (the optimal dose determined by titration) to 20.5 mg at the end of the 10-month maintenance phase. 11% of the children discontinued treatment due to side effects. 30% of parents spontaneously reported moderate to severe side effects (emotional outbursts, difficulty falling asleep, repetitive behaviors or thoughts, loss of appetite, irritability). During the titration phase, decreased appetite, sleep problems, and weight loss occurred more frequently with MPH than with placebo. Sleep problems and loss of appetite persisted during the maintenance phase, while other side effects decreased. Five children experienced single, transient increases in heart rate and blood pressure. (RCT with an open-label maintenance phase, n = 183, 1 year, E 1b.)⁴⁵

In 3- to 5-year-olds, immediate release MPH (titrated to a maximum of 1.25 mg/kg/day in two doses) reduced ADHD symptoms compared with placebo (ES −0.55, 95% CI −0.99 to −0.10). No child discontinued treatment due to side effects. MPH caused more mild side effects (332 events compared with 227 under placebo), but not more moderate or severe ones, and a more pronounced decrease in appetite (ES 0.75, 95% CI 0.35 to 1.15). (RCT, n = 153, 8 weeks, E 1b.)⁴⁶

For more information, visit ⇒ Dosage of Medications for ADHD.

6.3.5. Gene variants influence MPH levels¶

A small percentage of people with ADHD require a significantly lower dose of MPH.

Learn more about how CES1 gene variants influence the effects of MPH at Factors Affecting the Potency of MPH in the article “ : MPH, Part 3: Metabolism, Potency”.

6.4. Side Effects During the Initial Adjustment to Methylphenidate¶

In the first few days, taking the medication may be accompanied by a sensation as if it had snowed (as if everything were wrapped in cotton). This sensation (which is usually very pleasant) stems from the reduction in sensory overload and, like most side effects, disappears within a few days.
Others describe the initial effect as the amazing experience of having a clear head for the first time in their lives, with their thoughts no longer racing.

Side effects such as headaches, sleep problems, or others rarely occur. Most side effects subside within the first few weeks after titration. The risk of such side effects can be significantly reduced by a very slow titration (as described above). (Textbook, E 4)³³ A study with individually flexible dose adjustment reported a significantly lower rate of study discontinuation due to side effects (2.3%) (Open-label extension study of an RCT, n = 298, 26 weeks, manufacturer-funded (Novartis), E 2b.)⁴⁹ as an open-label one-year study in which OROS-MPH was titrated weekly in 18-mg increments starting at 36 mg/day up to a maximum of 108 mg/day (18.5%). In this study, the discontinuation rate due to adverse effects was highest at the starting dose of 36 mg/day (8.5%). (Open-label dose-titration study, n = 550, 6 to 12 months, manufacturer-funded, author(s) employed by the manufacturer, E 2b.)⁵⁰ The authors attributed the lower discontinuation rate to flexible dose optimization. (Review, authors partly employed by the manufacturer (Novartis), E 4.)¹⁷

To date, no study of adults known to us has explicitly prohibited caffeine consumption during dosing. Since caffeine can exacerbate side effects during dosing, the incidence of side effects is likely to decrease if caffeine intake is consistently avoided, compared to the study results. (Assessment by ADxS.)

Headaches can sometimes be reduced or prevented by drinking enough fluids and eating regularly (including glucose, if necessary). Since stimulants reduce the feeling of hunger, this can lead to reduced fluid and food intake, which can contribute to headaches.

A study found that MPH did not cause sleep problems. This may differ from the results of other studies because this study lasted a relatively long time—16 weeks—so that the side effects associated with tolerance were no longer noticeable. (RCT, n = 50, 16 weeks, E 1b)⁵¹ In contrast, a small study that lasted only 14 days found reduced sleep duration and delayed sleep onset in children treated with sustained-release MPH. (Placebo-controlled crossover study, n = 26, 2 weeks each, E 2a)⁵²

A greater increase in blood pressure 45 minutes after the first dose of MPH (0.3 mg/kg, immediate release) correlated with greater reduction in ADHD symptoms after 6 months in children and adolescents. The increase explained 4.2 to 5.5% of the variance in symptom improvement; there was no association with oppositional behavior. (Retrospective cohort study, n = 171, 6 months, E 2b.)⁵³

6.5. Symptoms of an MPH Overdose¶

When MPH is administered at the appropriate dose, the ability to concentrate increases, while internal tension and any hyperactivity decrease. If the latter symptoms reoccur at higher doses, this is a sign that the dose is too high.
Methylphenidate closes the stimulus filter (which is too open in people with ADHD). A typical reaction among people with ADHD who are taking the appropriate dosage is that they come back to themselves—they feel more like their true selves.

If the person with ADHD notices that MPH makes them jittery (even though they are not consuming caffeine [theine is just another name for caffeine] or theobromine [dark cocoa]), they should nevertheless continue to increase the dose cautiously at first. It has been observed on several occasions that such side effects disappeared after a few days or upon moving to the next higher dose. If this jitteriness persists, the dosage is too high. This also applies if concentration becomes too intense—that is, if the stimulus filter is restricted too much. Diminished emotional responsiveness (“zombie effects”) is a clear indication of an overdose.

MPH Poisoning¶

Among 32 children and adolescents (ages 2 to 17) treated in a Turkish pediatric emergency department following an overdose of MPH alone (at least 2 mg/kg, median 4.5 mg/kg, up to 14 mg/kg), ingestion was predominantly intentional (84%, including 24 suicide attempts). 59% remained symptom-free. The remaining patients experienced:

• Rapid heartbeat (tachycardia) in 38% of cases
• High blood pressure in 34% of cases
• Agitation at 22%
• dilated pupils in 19% of cases
• Seizures in 16% of cases

Most cases were mild and resolved within 12 hours. One toddler exhibited neuropsychiatric symptoms but made a full recovery within 48 hours. The dose ingested did not predict the onset of symptoms. (Case series, retrospective, n = 32, E 4.)⁵⁵

Data from poison control centers show that MPH is most commonly involved in cases of poisoning among children with ADHD caused by ADHD medications:

• 63% of 1,175 poison control calls regarding ADHD stimulants in children under 5 years of age in Australia (2004 to 2019) involved MPH. 94% were accidental, mostly involving a sibling’s medication. 34% were referred to the hospital. MPH poisonings increased by 5.2% per year in absolute terms but decreased by 6.9% per year relative to the number of prescriptions dispensed. (Retrospective analysis of poison control center data, n = 1,175, E 3.)⁵⁶
• 46.2% of the 156,365 cases of exposure to ADHD medications among 0- to 19-year-olds reported to U.S. poison control centers (2000–2014) involved MPH, 44.5% involved amphetamine medications. The most common cause was dosing errors (41.6%). Among adolescents, half of the exposures were intentional (suicide attempts, misuse). 60.4% did not require inpatient treatment, while 6.2% were admitted to the hospital. Three adolescents died after intentional ingestion (two after taking amphetamine medications, one after taking MPH). (Retrospective analysis of poison control center data, n = 156,365, E 3.)⁵⁷

6.6. Even if MPH is effective, and especially if there are side effects or if you do not respond, try different MPH medications¶

Many people with ADHD report experiencing side effects with one MPH medication that they do not experience with another MPH medication. In this context, there are reports that one MPH medication (in this case, Medikinet) had no effect, while another (in this case, Concerta) worked well.
Other people with ADHD report that they experienced increased aggression while taking one medication (in this case, Concerta), which did not occur with another MPH medication (Medikinet or medication with immediate release of MPH).
Still others experience a stronger rebound effect (increased restlessness as the effects wear off) with Medikinet than with other MPH medications. (Experience ADxS)

The various MPH formulations exhibit very different release profiles. In addition, depending on the manufacturer, MPH is incorporated into different excipients.
In cases of wheat allergy, MPH embedded in wheat starch is unsuitable. In cases of celiac disease, the low gluten content of wheat starch (Ritalin® contains no more than 4.8 µg per tablet) is considered very unlikely to cause problems. MPH containing lactose should not be taken in cases of rare hereditary galactose intolerance, complete lactase deficiency, or glucose-galactose malabsorption. (Prescribing Information, E 4.)⁶⁰

In adults, once-daily OROS-MPH (an average of 80.9 mg/day) caused dry mouth more frequently (37% vs. 22%), decreased appetite (36% vs. 11%), and gastrointestinal symptoms (29% vs. 17%) than immediate release MPH taken three times daily (average 74.8 mg/day). Weight loss was slightly greater with OROS-MPH (2.8 vs. 2.1 kg, p = 0.03). There was barely any difference in discontinuations due to side effects (OROS-MPH 9 of 67, immediate release MPH 14 of 102) or efficacy. No serious adverse events occurred. (Pooled analysis of two placebo-controlled RCTs, n = 285, 6 weeks, non-randomized drug comparison, E 2a.)⁶¹

After switching from immediate release MPH to OROS-MPH at a comparable daily dose, tics decreased in children (ages 6 to 12) (27.7% versus 19.6%). There was no difference in loss of appetite (24.8% vs. 22.7%) or sleep disturbances (8.9% vs. 8.2%). A natural decline in tics could not be ruled out. (Open-label study, n = 102, 4 weeks, E 2b.)⁶² Children who switched from immediate release MPH to OROS-MPH due to poor adherence had a similar adverse effect profile in an intraindividual comparison. (Open-label study, n = 607, of whom n = 124 switched; full text not available to us, E 2b.)⁶³

Dexmethylphenidate (average 18.25 mg/day) was similarly effective and well-tolerated in 6- to 17-year-olds as racemic MPH (average 32.14 mg/day). No child discontinued the study due to side effects while taking dexmethylphenidate; two children each discontinued while taking racemic MPH and placebo. The most common side effects were headaches (15.9% on dexmethylphenidate, 21.7% on racemic MPH, 9.5% on placebo), nausea (11.4%, 13.0%, 2.4%), and loss of appetite (9.1%, 10.9%, 0%). No serious side effects occurred. (RCT, n = 132, 4 weeks, manufacturer-funded, author(s) employed by the manufacturer, E 1b.)⁶⁴

Switching to Amphetamine-Based Medications¶

If none of the MPH preparations produce a satisfactory response (the typical non-responder rate is just under 30%), treatment with amphetamine-based medications should always be initiated. This allows an additional 70 to 80 percent of MPH nonresponders to be treated satisfactorily, thereby reducing the overall nonresponder rate for MPH and amphetamine to less than 10 percent.
If dysthymia or depression persists despite MPH otherwise having a satisfactory effect, switching to amphetamine-based medications may also be considered, as these also have a mild serotonergic effect.

In a double-blind crossover study in children (ages 5 to 15), six side effects were more pronounced with dexamfetamine (0.15 mg/kg per dose) than with MPH (0.3 mg/kg per dose): insomnia, irritability, tearfulness, anxiety, sadness, and nightmares. No side effect was more pronounced with MPH than with dexamfetamine. With MPH, the number and severity of “side effects” reported by parents were lower than the baseline value before treatment (number 7.19 vs. 8.19, severity 3.24 vs. 4.08). Only decreased appetite was more pronounced with MPH than before treatment. Two children (1.6%) discontinued treatment with each of the two stimulants due to severe side effects. (RCT [crossover, double-blind, without placebo], n = 125, 2 weeks each, E 1b.)⁶⁵

Antidepressant effects have been observed with daily doses of MPH ranging from 10 to 30 mg and with daily doses of AMP ranging from 5 to 60 mg. (textbook; full text not available to us; E 4)¹⁰

6.7. Circumstances Surrounding Prescription and Use¶

Some people with ADHD need to take their MPH medication at exactly the same time every day.
Care should be taken to ensure that the medication is taken in such a way that it provides coverage throughout the entire day. However, the last doses of the day must be taken early enough so that the medication’s effects have worn off by bedtime.

Treatment breaks (drug holidays)¶

Planned treatment breaks (drug holidays) showed mixed results in:

• Weekend breaks for boys (MPH 0.3 to 0.7 mg/kg/day): no significant increase in symptoms on the weekend (ES 0.26) or on the following school day (ES 0.002), fewer sleep problems (p = 0.05), and a tendency toward less loss of appetite (p = 0.08) (RCT, double-blind, n = 40, 28 days, E 1b.)⁶⁷
• Weekend breaks among adult men on stable MPH treatment: more procrastination (8.4 vs. 7.5 in the diary, p = 0.028) and fewer tasks completed (64.8% vs. 74.1%, p = 0.017); not significant on weekdays alone; no differences in sleep, appetite, cognition, and adherence; more frequent increases in blood pressure and palpitations (Prospective cohort study, non-randomized, n = 43, 28 days, full text not available to us, E 2b.)⁶⁸
• 8-week summer break for children: Irritability, which had been reduced by MPH, returned to baseline levels, while improved emotional recognition (Reading the Mind in the Eyes Test) was maintained (Prospective cohort study, n = 56, of whom 39 completed the study, E 2b.)⁶⁹
• 2-month summer break for 9- to 17-year-olds: Improvements in theory of mind and affect perception were maintained among participants who completed the study (Prospective cohort study, n = 56, of whom 12 completed the study, E 2b.)⁷⁰

In double-blind, placebo-controlled discontinuation trials (N-of-1, crossover) conducted in clinical practice after at least one year of MPH treatment, only the hyperactivity and impulsivity symptoms assessed by teachers were less severe with MPH than with placebo. According to clinicians, 17 of 21 children and adolescents (81%) did not experience a worsening of symptoms while on placebo. 61.5% continued MPH after completing the discontinuation trial, 7 of whom showed no worsening of symptoms while on placebo, according to clinicians. Another 5 (19.2%) discontinued the placebo phase prematurely due to lack of effect and also continued MPH. (RCT, N-of-1 crossover, n = 26, 2 weeks each, E 1b.)⁷¹

6.8. Effect on People Not Affected¶

MPH can also be effective in people who do not have ADHD. It can (at low doses) increase attention, just as mild stress enhances cognitive performance by slightly raising levels of norepinephrine and dopamine in the prefrontal cortex (PFC).
A higher dose in unaffected individuals (such as a low dose in people who already have slightly elevated dopamine or norepinephrine levels) can cause such a significant increase in DA and NE levels that it triggers ADHD symptoms.
In ADHD, the (tonic) dopamine level in the striatum is too low, which causes many ADHD symptoms. When properly dosed, MPH raises dopamine levels in the striatum to the optimal level. However, if dopamine levels are raised above the optimal level (due to an overdose in people with ADHD or when MPH is taken by healthy individuals), this triggers the same symptoms as those seen in ADHD, because neurotransmitter communication functions optimally only at the correct neurotransmitter level. (Textbook, E 4)⁷²

A single dose of 60 mg MPH increased the heart rate (Emax 91.6 vs. 73.1 beats/min with placebo) and systolic blood pressure (Emax 145 vs. 135 mm Hg) to a similar extent as MDMA (125 mg) and modafinil (600 mg). Unlike MDMA, MPH increased subjective anxiety (STAI-State Emax 42.0 vs. 36.6) and, like modafinil, increased the misclassification of facial expressions as angry. (RCT, double-blind, placebo-controlled, crossover, n = 24, single dose, E 1b.)⁷³

In healthy adults who were not sleep-deprived, a single dose of MPH only slightly improved overall cognitive performance (SMD 0.21, 95% CI 0.09 to 0.32). The most pronounced improvement was observed in recall (SMD 0.43, 95% CI 0.20 to 0.65), followed by sustained attention (SMD 0.42) and inhibition (SMD 0.27). Working memory updating, task switching, and spatial working memory did not improve. (meta-analysis, k = 24, N = 645, E 1a.)⁷⁴ 20 mg of immediate-release MPH improved delayed recall of learned words after 24 hours in healthy young men and reduced self-reported fatigue, but did not affect sustained attention, working memory, processing speed, logical thinking, or creativity. The effects were small. (RCT, n = 48 (3 arms: MPH, modafinil, caffeine, each versus placebo), single dose, E 1b.)⁷⁵

Animal studies using animals that are not ADHD models¶

Amphetamine-based medications also have a positive effect (at low doses) on unaffected male mice: (animal study, n = 22, mice, E 2b)⁷⁶

• False alarms significantly reduced in both males and females
• Reduced hit rate for females
• As a result, CPT performance improved (only) in males
• Orientation and physical engagement in response to task stimuli remain unaffected

6.9. MPH in Old Age¶

There is no explicit restriction on the use of methylphenidate in older adults. The MPH prescribing information states that MPH should not be prescribed to older adults. In contrast, there is no such statement for lisdexamfetamine, despite the equally insufficient data.
Treatment with MPH in older adults may nevertheless constitute off-label prescribing. (review article, E 4)⁷⁹

There is no evidence to suggest that MPH causes difficulties in old age.
A small study reported good tolerability among older people with ADHD. (case series, n = 11, E 4)⁸⁰
In addition, MPH is also used to treat depression in older adults. (Systematic review, k = 5, E 2a)⁸¹

Of 113 adults with ADHD aged 55 to 79 years at a specialized outpatient clinic in the Netherlands, 56 received MPH (average starting dose: 34.7 mg for immediate release, 26.8 mg for sustained release). 65% reported a positive effect; 42.7% discontinued the medication during the course of treatment due to side effects or lack of effect. While on MPH, heart rate increased slightly (from 69.2 to 73.3 beats/min) and weight decreased slightly (from 81.0 to 80.2 kg); blood pressure did not change at the group level. (Retrospective cohort study, n = 113, E 2b.)⁸² Among U.S. veterans aged 50 and older, the rate of serious cardiovascular events (heart attack, stroke/TIA, arrhythmia) did not differ between the MPH group and the amphetamine/dextroamphetamine group (4.1% vs. 5%, p = 0.66). (Retrospective cohort study, n = 436, full text not available to us, E 2b.)⁸³

In Denmark, MPH was predominantly used in people aged 50 and older for indications other than ADHD. Of 6,690 new users of ADHD medications (median age 62 years, 98% MPH, predominantly with immediate release), only 2% had a diagnosis of ADHD, while 52% had cancer. The one-year mortality rate was 50%, predominantly among cancer patients. The authors interpret this as off-label use in palliative care. (registry study, n = 6,690, E 2b.)⁸⁴

6.10. International Guidelines for Treatment with Methylphenidate¶

6.10.1. United States: AAP Guidelines, 2011, 2019¶

(E 4): “Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents,” guideline from the American Academy of Pediatrics (Guideline, E 4.)⁸⁵ * (Guideline, E 4)*⁸⁶

Children, Adolescents:
Start with a low dose, as the response to stimulants varies from person to person and is unpredictable. Preschoolers (ages 4 to 5) metabolize MPH more slowly and should therefore start with a low dose, which should be increased in small increments. Maximum doses have not been sufficiently studied in preschool-aged children. Do not calculate the dose based on mg/kg, as the required dose is not related to height or weight. (Guideline, E 4.)⁸⁶
Increase in 7-day increments (in urgent cases, in 3-day increments)
Goal: The dose that provides maximum benefit with tolerable side effects. (Guideline, E 4.)⁸⁶ The 2011 version stated that the goal was to minimize side effects. (Guideline, E 4.)⁸⁵
This guideline does not specify dosage levels.

For treatment-resistant cases, combination therapy may also be used.

6.10.2. Canada: CADDRA Guidelines/CAP Guidelines, 2011¶

Children, Adolescents, Adults: (Guideline, E 4)⁸⁷
Start with low doses of medication and gradually increase the dose until the dose that improves symptoms and functional ability and has a good side-effect profile is reached.

6.10.3. Australia: AADPA Guideline (approved by the NHMRC), 2023¶

Children, Adolescents, Adults: (Guideline, E 4)⁸⁸

Joint selection of appropriate medications by doctors and people with ADHD/guardians.
Personalized Medication Selection
Dose titration with regular medical monitoring of progress regarding symptoms, functional levels, and adverse effects
Optimal dose: The dose that reduces symptoms and improves functional outcomes while minimizing adverse effects

6.10.4. New Zealand: Guidelines from the New Zealand Ministry of Health, 2001¶

The New Zealand guidelines do not appear to be freely available on the Internet. The only versions found have unclear copyright information.

Children, Adolescents, and Adults: (Guideline, E 4.)⁸⁹
Start dosing at the lower end of the dosage range (approximately 0.1 to 0.2 mg/kg MPH or 0.05 to 0.1 mg/kg DAMP).
Customized titration as needed
Titration rate based on the intensity of monitoring for efficacy and side effects (e.g., 5 to 7 days to allow the patient to adjust to initial side effects such as stomach upset or tearfulness)
Optimal dose: the smallest dose that produces an optimal therapeutic response
Maximum dose:

• MPH: 60 mg/day (effective dose range: 0.3 to 1.0 mg/kg)
• Dexamfetamine: 20 mg/day; older children, 40 mg/day (effective dose range: 0.15 to 0.5 mg/kg)

If there is no improvement

• Check compliance with the medication regimen
• Review the diagnosis, differential diagnoses, and comorbidities
• Adjust the dosage
• Change the active ingredient

Treatment with stimulants (MPH or dextroamphetamine) is the first-line treatment.
Additional interventions (including behavioral therapy) can be specifically targeted at remaining symptoms once the symptoms are under control after several months of optimally titrated medication. (Guideline, E 4.)⁸⁹

6.10.5. Malaysia: Malaysian Guidelines, 2008, 2020¶

Children ages 6 and older, adolescents (2020 version): (Guideline, E 4.)⁹⁰
MPH: Ages 6 and up
Start with a low dose:

• Immediate release MPH: 5 mg once or twice daily, with a weekly increase of 5 to 10 mg/day
• MPH LA: 20 mg once daily, with a weekly increase of 10 mg/day
• OROS-MPH: 18 mg once daily, with a weekly increase of 18 mg

Maximum dose:

• OROS-MPH: 72 mg/day
• Immediate release MPH: 60 mg/day in 2 to 3 separate doses, not to exceed 2 mg/kg/day
• MPH LA: 60 mg/day

2008 version: (Secondary citation from Huss et al. (2017): Narrative review, manufacturer-funded, authors employed by the manufacturer, E 4.)¹⁷
Start with a dose at the lower end of the dosage range

• 2.5 mg/day for children aged 3–5 years
• 5 mg/day for an 8-year-old
• 10 mg/day for children over 8 years of age

Goal: Maximum effectiveness with minimal side effects
Maximum dose:

• 60 mg/day
• 30 mg/day, for children ages 3–5

6.10.6. Europe: ESCAP Guidelines, 2004¶

Children, adolescents, adults: (Guideline, Expert Consensus, E 4)⁹¹
Start with a low dose (0.2 mg/kg per dose for children and adolescents)
Increase the dose until a good result is achieved, or until adverse effects occur, or until the maximum dose is reached (0.7 mg/kg per dose for children and adolescents)—whichever occurs first

6.10.7. Germany: S3 Guideline, 2018, 2026¶

Children, Adolescents, Adults: (Guideline, E 4)⁹² * (Guideline, E 4.)*⁹³
Start: low initial dose
Increase the dose until no further clinically significant improvement in symptoms (e.g., in terms of core symptoms, but also in terms of a change in problem behavior) can be achieved and the adverse effects remain tolerable
Goal: the lowest possible dose
The approved maximum daily dose should only be exceeded in justified exceptional cases. (Guideline, E 4.)⁹²
Version 2.0 (2026) reproduces the titration comment verbatim. Long-acting formulations should be used preferentially in such cases (2018: “may be considered”). (Guideline, E 4.)⁹³

The guideline from the ADHD Working Group of Pediatricians (as of 2009) stated:“For stimulants: No strict correlation between body weight and the required dose!(Level of evidence IIa). Always titrate individually. The mg/kg body weight values provided are averages and may be lower or higher on a case-by-case basis.” (Guideline from a professional association, E 4.)⁹⁴

MPH:
The S3 guideline does not specify any concrete titration steps. Like Kühle, we believe that titration in small increments is sensible, even if this tests the persistence of some people with ADHD. (E 4.)³⁵ For this purpose, immediate release MPH (2.5 mg per single dose) or sustained release MPH (5 mg per single dose, which—due to its twice-as-long duration of action—is equivalent to two consecutive doses of 2.5 mg of immediate release MPH) can be used. (ADxS assessment)

6.10.8. United Kingdom: BAP Guidelines, 2007, 2014¶

(E 4): Children, Adolescents, Adults: (Guideline, expert consensus, industry-funded, E 4.)⁹⁵ * (Guideline, expert consensus, E 4)*⁹⁶
Titration to the optimal dose over a period of 4 to 6 weeks
Maximum dose:

• 60 mg/day for adolescents and children
• 100 mg/day for adults

For treatment-resistant cases, combination therapy may also be used.

6.10.9. England and Wales: NICE Guidelines CG72 (2008, updated 2016), NG87 (2018, updated 2019)¶

The current NG87 guideline does not specify dosages and refers to the British National Formulary (BNF) for this information. (Guideline, E 4.)⁹⁷
MPH (short- or long-acting) is the first-line treatment for children ages 5 and older and adolescents.
Titration based on symptoms and side effects, with recording on standard scales at each dose adjustment and regular follow-up (e.g., weekly phone calls)
Goal: fewer symptoms, behavioral improvement, and improvements in education, work, and relationships, with tolerable side effects

The previous guideline, CG72, cited: (Secondary citation via Huss et al. (2017): narrative review, manufacturer-funded, authors employed by the manufacturer, E 4.)¹⁷

Children, Adolescents:
Initial treatment starting with low doses

• 5 mg (immediate release) two or three times a day, or
• sustained release

Titration based on symptoms and side effects over 4–6 weeks until the dose is optimized
Maximum dose: 60 mg/day

Adults:
Initial treatment starting with low doses

• 5 mg three times a day (immediate release)
• sustained release: corresponding dose

Titration based on symptoms and side effects over 4–6 weeks until the dose is optimized
Maximum dose: 100 mg/day

6.10.10. Scotland: SIGN Guidelines, 2009¶

This guideline has been withdrawn. In 2019, SIGN rejected a revised edition, citing the 2018 NICE guideline. (E 4.)⁹⁸

Children, Adolescents: (Guideline, E 4)⁹⁹
Structured Titration Protocol for Determining the Optimal Drug Dose

6.10.11. Spain: Spanish Guidelines, 2010¶

Children, Adolescents: (Guideline, E 4)¹⁰⁰
Start with low doses of immediate release MPH (2.5 or 5 mg depending on weight, 2 to 3 times a day, no later than 5:00 p.m.)
Gradual increase of 2.5 to 5 mg per week, depending on clinical response and side effects
Dosage range: 0.5 to 2 mg/kg/day
Maximum dose: 60 mg/day

6.10.12. Sweden: Swedish Guidelines (2016)¶

, “Swedish Medical Products Agency ADHD Drugs – Treatment Guidelines”, are cited here as a secondary reference via Huss et al. (Narrative review, manufacturer-funded, authors employed by the manufacturer, E 4.)¹⁷

Children, Adolescents:
Start with low doses (18 mg for long-acting medications, 5–10 mg for intermediate-acting medications)
Gradual adjustment (about once a week)
Goal: A dose that is effective and well tolerated

Adults:
Start with low doses
Gradual adjustment (about once a week)
Goal: A dose that strikes the best balance between efficacy and side effects
Maximum dose: 80 mg/day

The dose escalation should not be stopped too early. It is better to try a higher dose, which can be reduced if side effects occur. (Secondary citation from Huss et al. (2017): Narrative review, manufacturer-funded, authors employed by the manufacturer, E 4.)¹⁷

7. Sustained release or immediate release MPH¶

This section has been moved to Sustained-Release MPH, Sustained-Release Techniques in the post MPH Part 3: Retardation.

8. Carriers¶

• Ritalin (immediate release): wheat starch and lactose (E 4.)³²
• Medikinet (immediate release): cornstarch and lactose (E 4.)³²
• Equasym Retard: sucrose and cornstarch (sugar beads) (E 4.)³²

9. Efficacy of Methylphenidate¶

Methylphenidate is the first-line treatment for children. Carefully titrated medication improved ADHD symptoms more significantly after 14 months than intensive behavioral therapy. (RCT, n = 579, ages 7 to 9.9 years, 14 months, E 1b.)¹⁰¹ After 36 months, there was no longer a difference between the groups. Meanwhile, 45% of the behavioral therapy group (previously 14%) were taking medication, while in the medication group, the proportion dropped from 91% to 71%. (Follow-up of an RCT, n = 485, 36 months, E 2b.)¹⁰²

Since stimulants establish or enhance the ability to learn and undergo therapy, it makes sense to start by using stimulants on an acute basis while, at the same time, using behavioral therapy and/or neurofeedback to lay the groundwork for eventually weaning the patient off them. (ADxS Assessment)

(E 1a): The mean effect size (SMD) of MPH on core ADHD symptoms is approximately 0.8 to 1.0 in children and adolescents and approximately 0.5 in adults. (Network meta-analysis, k = 133, n = 10,068 children and adolescents, n = 8,131 adults, E 1a.)¹⁰³ * ([Cochrane] meta-analysis, k = 185 RCTs [38 parallel-group studies with n = 5,111, 147 crossover studies with n = 7,134], 96.8% of the studies had a high risk of bias, E 1a.)¹⁰⁴ * (Narrative review, E 4.)¹⁰⁵

For information on the effectiveness of individual medications and treatment options, see ⇒ Effect sizes of various ADHD treatments in the chapter ⇒ Treatment and Therapy.

Taking an MPH medication in combination with noradrenergic medications or zinc can further enhance its effectiveness. However, a cautious approach is recommended here. It is advisable to consult a doctor with experience in treating ADHD with medication.